Shares subject to the option vest 1/4 annually over a four (4) year period beginning on August 3, 2013.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Endocyte makes a similar move, sign up!
Other recent filings from the company include the following:
Endocyte's President and CEO just cashed-in 3,000 options - Dec. 4, 2013